<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01675674</url>
  </required_header>
  <id_info>
    <org_study_id>RHE-001</org_study_id>
    <nct_id>NCT01675674</nct_id>
  </id_info>
  <brief_title>Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics</brief_title>
  <official_title>Unrecognized Mucopolysaccharidosis I, II, IVA, and VI in the Pediatric Rheumatology Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National MPS Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MediResource Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National MPS Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to learn how many children and young adults who come to pediatric
      rheumatology clinics may have mucopolysaccharidosis (MPS). The study tests for 4 of the types
      of MPS: I, II, IVA, and VI. This can help researchers decide whether to create a screening
      program for MPS at pediatric rheumatology clinics. This study is being done in rheumatology
      clinics because the first symptoms of MPS are often joint problems such as stiff joints, and
      rheumatologists may be the first doctors that a patient with MPS visits. The study will also
      evaluate the utility of dried blood spot testing for MPS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MPS, or mucopolysaccharidosis (mew-co-paw-lee-sack-a-rid-o-sis), disorders are a group of
      rare inherited diseases that affect about 1 in every 25,000 people in the United States.
      There are 7 MPS disorders: MPS I (Hurler, Hurler-Scheie, and Scheie syndromes), II (Hunter
      syndrome), III (Sanfilippo syndrome), IV (Morquio syndrome), VI (Maroteaux-Lamy syndrome),
      VII (Sly syndrome), and IX (no other name). In people who have MPS, the body cannot break
      down certain materials in the body's cells. These materials then build up in the cells,
      causing problems such as stiff joints, misshapen bones, curled hands and reduced hand
      function, frequent ear infections, vision and hearing problems, &quot;thickened&quot; facial features,
      and heart problems. Getting access to diagnosis and treatment can help make MPS easier to
      manage; but unfortunately, people with MPS may go undiagnosed for many years.

      This study is being done to learn how many children and young adults who come to pediatric
      rheumatology clinics may have mucopolysaccharidosis (MPS). The study tests for 4 of the types
      of MPS: I, II, IVA, and VI. This can help researchers decide whether to create a screening
      program for MPS at pediatric rheumatology clinics. This study is being done in rheumatology
      clinics because the first symptoms of MPS are often joint problems such as stiff joints, and
      rheumatologists may be the first doctors that a patient with MPS visits.

      The study will use dried blood spot (DBS) testing to screen for these types of MPS. It will
      also use a survey to evaluate the utility and convenience of dried blood spot testing for
      MPS.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding withdrawn due to insufficient enrollment rate
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Incidence of previously unrecognized MPS I, II, IVA, and VI in children presenting to pediatric rheumatology, hand, or skeletal dysplasia clinics</measure>
    <time_frame>At study completion (approximately 18 months after the beginning of the study)</time_frame>
    <description>Each patient is screened for MPS I, II, IVA, and VI after enrolling in the study. The results for all patients will be pooled when the study is completed (expected completion approx. 18 months after the study begins).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Utility of DBS testing to screen for MPS in pediatric patients</measure>
    <time_frame>At study completion (approximately 18 months after the beginning of the study)</time_frame>
    <description>For the secondary endpoint (utility of DBS testing), the following data will be collected: ease of taking and sending the DBS sample; number of errors of sample taking; adverse events (if any) associated with blood sampling by finger prick or venipuncture (for subjects over one year of age; choose whichever method is most convenient) or heel prick (for subjects under one year of age); and comfort of patients and/or their parents with the test.
Study personnel who performed DBS testing will also be asked to complete a brief survey about the utility of DBS testing.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Mucopolysaccharidoses</condition>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>Mucopolysaccharidosis IV</condition>
  <condition>Mucopolysaccharidosis VI</condition>
  <arm_group>
    <arm_group_label>Dried blood spot test for MPS</arm_group_label>
    <description>For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE &quot;highly suspicious&quot; symptom or at least TWO &quot;less suspicious&quot; symptoms that may be indicative of an MPS disorder (see inclusion criteria).
For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE &quot;highly suspicious&quot; symptom or at least TWO &quot;less suspicious&quot; symptoms that may be indicative of an MPS disorder (see inclusion criteria).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dried blood spot test for MPS</intervention_name>
    <description>The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).</description>
    <arm_group_label>Dried blood spot test for MPS</arm_group_label>
    <other_name>DBS testing</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        For the prospective study, subjects will be drawn from all children (aged 6 months to 18
        years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric
        hand, or skeletal dysplasia clinic), with at least ONE &quot;highly suspicious&quot; symptom or at
        least TWO &quot;less suspicious&quot; symptoms that may be indicative of an MPS disorder (see
        inclusion criteria).

        For the retrospective chart review, subjects will be drawn from all children who were 6
        months to 18 years of age at the time of first presentation to selected clinics (pediatric
        rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE &quot;highly
        suspicious&quot; symptom or at least TWO &quot;less suspicious&quot; symptoms that may be indicative of an
        MPS disorder (see inclusion criteria).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of presenting to the pediatric rheumatology, pediatric hand, or skeletal
             dysplasia clinic with at least ONE &quot;highly suspicious&quot; symptom or at least TWO &quot;less
             suspicious&quot; symptoms that may be indicative of an MPS disorder (see below):

             Highly suspicious symptoms:

               -  characteristic facial features

               -  hearing loss

               -  corneal clouding

               -  cardiac manifestations

               -  dysostosis multiplex

               -  hepatosplenomegaly

               -  spinal cord compression

               -  hydrocephalus

               -  carpal tunnel syndrome

               -  delayed mental development or regression in mental development

             Less suspicious symptoms:

               -  short stature

               -  extensive Mongolian spots

               -  sleep apnea

               -  copious nasal discharge

               -  recurrent otitis media, ear fluid that will not drain, or the presence of ear
                  tubes

               -  frequent upper respiratory tract infections

               -  joint stiffness or limited range of motion

               -  hand problems (Claw hands or reduced hand function)

               -  hernia (inguinal or umbilical)

               -  abnormally shaped teeth

               -  dental cysts

               -  tooth abscess

          2. Age of at least 6 months.

          3. Age under 18 years at time of initial clinic presentation.

          4. Written, signed, and dated informed consent obtained from the subject (if 18 years of
             age) or the subject's parents (if under 18). Written, dated, and signed assent from
             children is also required at some centers.

        Exclusion Criteria:

          1. Under 6 months of age.

          2. Over 18 years of age at initial clinic presentation.

          3. Patients who have had confirmation of an MPS disorder by biochemical analysis and/or
             by molecular biology.

          4. Patients for whom MPS enzyme activity tests (i.e., enzyme levels tested in
             fibroblasts, leukocytes, serum, or blood spots) have already been performed, and for
             which the result was normal. (Patients who have been screened for MPS through urinary
             GAG and tested normal will not be excluded from the study.)

          5. Written informed consent not available.

          6. Subject unwilling or unable to provide the necessary blood spot for analysis.

          7. Any other condition that would, in the opinion of the investigator, interfere with the
             participant's ability to provide informed consent, comply with study instructions, or
             possibly confound interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas JA Lehman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Division of Pediatric Rheumatology, Hospital for Special Surgery; Professor of Clinical Pediatrics, Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cimaz R, Coppa GV, Koné-Paut I, Link B, Pastores GM, Elorduy MR, Spencer C, Thorne C, Wulffraat N, Manger B. Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J. 2009 Oct 23;7:18. doi: 10.1186/1546-0096-7-18.</citation>
    <PMID>19852785</PMID>
  </reference>
  <reference>
    <citation>Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschütter A, Kampmann C, Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28(6):1011-7.</citation>
    <PMID>16435194</PMID>
  </reference>
  <reference>
    <citation>Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, Chao MC, Chiu PC, Lin SJ, Tsai LP, Hwu WL, Lin JL. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A. 2009 May;149A(5):960-4. doi: 10.1002/ajmg.a.32781.</citation>
    <PMID>19396827</PMID>
  </reference>
  <reference>
    <citation>Malm G, Lund AM, Månsson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008 Nov;97(11):1577-81. doi: 10.1111/j.1651-2227.2008.00965.x. Epub 2008 Aug 4. Erratum in: Acta Paediatr. 2008 Dec;97(12):1773.</citation>
    <PMID>18681890</PMID>
  </reference>
  <reference>
    <citation>Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008 Sep 16;3:24. doi: 10.1186/1750-1172-3-24.</citation>
    <PMID>18796143</PMID>
  </reference>
  <reference>
    <citation>Murphy AM, Lambert D, Treacy EP, O'Meara A, Lynch SA. Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish republic. Arch Dis Child. 2009 Jan;94(1):52-4. doi: 10.1136/adc.2007.135772. Epub 2008 May 7.</citation>
    <PMID>18463126</PMID>
  </reference>
  <reference>
    <citation>Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003 Dec 15;123A(3):310-3. Review.</citation>
    <PMID>14608657</PMID>
  </reference>
  <reference>
    <citation>Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999 Jul-Aug;105(1-2):151-6.</citation>
    <PMID>10480370</PMID>
  </reference>
  <reference>
    <citation>Verity C, Winstone AM, Stellitano L, Will R, Nicoll A. The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child. 2010 May;95(5):361-4. doi: 10.1136/adc.2009.173419. Epub 2009 Nov 29.</citation>
    <PMID>19948513</PMID>
  </reference>
  <reference>
    <citation>Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007 Aug;120(2):405-18. Review.</citation>
    <PMID>17671068</PMID>
  </reference>
  <reference>
    <citation>Muenzer J, Wraith JE, Clarke LA; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009 Jan;123(1):19-29. doi: 10.1542/peds.2008-0416.</citation>
    <PMID>19117856</PMID>
  </reference>
  <reference>
    <citation>Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, Link B, Martin RA, Molter DW, Muñoz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009 Dec;124(6):e1228-39. doi: 10.1542/peds.2008-0999. Epub 2009 Nov 9. Review.</citation>
    <PMID>19901005</PMID>
  </reference>
  <reference>
    <citation>Aldenhoven M, de Koning TJ, Verheijen FW, Prinsen BH, Wijburg FA, van der Ploeg AT, de Sain-van der Velden MG, Boelens J. Dried blood spot analysis: an easy and reliable tool to monitor the biochemical effect of hematopoietic stem cell transplantation in hurler syndrome patients. Biol Blood Marrow Transplant. 2010 May;16(5):701-4. doi: 10.1016/j.bbmt.2010.01.006. Epub 2010 Jan 21.</citation>
    <PMID>20096360</PMID>
  </reference>
  <reference>
    <citation>Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001 Dec;47(12):2098-102.</citation>
    <PMID>11719472</PMID>
  </reference>
  <reference>
    <citation>Chamoles NA, Blanco M, Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem. 2001 Apr;47(4):780-1. Erratum in: Clin Chem 2001 Dec;47(12):2192.</citation>
    <PMID>11274042</PMID>
  </reference>
  <reference>
    <citation>Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):397-404.</citation>
    <PMID>16763908</PMID>
  </reference>
  <reference>
    <citation>Wang D, Eadala B, Sadilek M, Chamoles NA, Turecek F, Scott CR, Gelb MH. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem. 2005 May;51(5):898-900. Epub 2005 Feb 3.</citation>
    <PMID>15695324</PMID>
  </reference>
  <reference>
    <citation>Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem. 2008 Dec;54(12):2067-70.</citation>
    <PMID>19042989</PMID>
  </reference>
  <reference>
    <citation>Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA, Meikle PJ. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin Chem. 2006 Apr;52(4):643-9. Epub 2006 Feb 23.</citation>
    <PMID>16497940</PMID>
  </reference>
  <reference>
    <citation>Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem. 2007 Jan;53(1):137-40. Epub 2006 Nov 2.</citation>
    <PMID>17082248</PMID>
  </reference>
  <reference>
    <citation>Wolfe BJ, Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome). Anal Chem. 2011 Feb 1;83(3):1152-6. doi: 10.1021/ac102777s. Epub 2010 Dec 30.</citation>
    <PMID>21192662</PMID>
  </reference>
  <reference>
    <citation>Parkinson-Lawrence EJ, Muller VJ, Hopwood JJ, Brooks DA. N-acetylgalactosamine-6-sulfatase protein detection in MPS IVA patient and unaffected control samples. Clin Chim Acta. 2007 Feb;377(1-2):88-91. Epub 2006 Sep 1.</citation>
    <PMID>17027703</PMID>
  </reference>
  <reference>
    <citation>Hein LK, Meikle PJ, Dean CJ, Bockmann MR, Auclair D, Hopwood JJ, Brooks DA. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta. 2005 Mar;353(1-2):67-74.</citation>
    <PMID>15698592</PMID>
  </reference>
  <reference>
    <citation>Duffey TA, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Anal Chem. 2010 Nov 15;82(22):9587-91. doi: 10.1021/ac102090v. Epub 2010 Oct 20.</citation>
    <PMID>20961069</PMID>
  </reference>
  <reference>
    <citation>Ashrafi MR, Shabanian R, Mohammadi M, Kavusi S. Extensive Mongolian spots: a clinical sign merits special attention. Pediatr Neurol. 2006 Feb;34(2):143-5.</citation>
    <PMID>16458829</PMID>
  </reference>
  <reference>
    <citation>Ochiai T, Suzuki Y, Kato T, Shichino H, Chin M, Mugishima H, Orii T. Natural history of extensive Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients. J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1082-5.</citation>
    <PMID>17714129</PMID>
  </reference>
  <reference>
    <citation>Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008 Mar;167(3):267-77. Epub 2007 Nov 23. Review.</citation>
    <PMID>18038146</PMID>
  </reference>
  <reference>
    <citation>Hendley JO. Clinical practice. Otitis media. N Engl J Med. 2002 Oct 10;347(15):1169-74. Review.</citation>
    <PMID>12374878</PMID>
  </reference>
  <reference>
    <citation>Rovers MM, Balemans WA, Sanders EA, van der Ent CK, Zielhuis GA, Schilder AG. Persistence of upper respiratory tract infections in a cohort followed from childhood to adulthood. Fam Pract. 2006 Jun;23(3):286-90. Epub 2006 Mar 3.</citation>
    <PMID>16517546</PMID>
  </reference>
  <reference>
    <citation>Tomatsu S, Nishioka T, Montaño AM, Gutierrez MA, Pena OS, Orii KO, Sly WS, Yamaguchi S, Orii T, Paschke E, Kircher SG, Noguchi A. Mucopolysaccharidosis IVA: identification of mutations and methylation study in GALNS gene. J Med Genet. 2004 Jul;41(7):e98.</citation>
    <PMID>15235041</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2012</study_first_posted>
  <last_update_submitted>May 23, 2013</last_update_submitted>
  <last_update_submitted_qc>May 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidoses</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Rheumatology</keyword>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Mucopolysaccharidosis IV</keyword>
  <keyword>Mucopolysaccharidosis VI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

